Key result
Prophylactic anticoagulation did not increase the incidence of symptomatic intracranial hemorrhage in patients with glioblastoma or brain metastases compared to controls.
Why the study?
Patients with glioblastoma or brain metastases and atrial fibrillation may face an increased risk of intracranial hemorrhage from anticoagulation, which required assessment.
Does prophylactic anticoagulation increase the risk of symptomatic intracranial hemorrhage in patients with glioblastoma or brain metastases and atrial fibrillation?
Cohort (n=258)
No
Does prophylactic anticoagulation increase the risk of symptomatic intracranial hemorrhage in patients with glioblastoma or brain metastases and atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Prophylactic anticoagulation for atrial fibrillation does not appear to significantly increase the risk of symptomatic intracranial hemorrhage in patients with glioblastoma or brain metastases over a 9-month follow-up.
PURPOSE: Patients with glioblastoma (GBM) or brain metastases (MET) and atrial fibrillation (AF) might be at an increased risk of intracranial hemorrhage (ICH) due to anticoagulation (AC). Our aim was to assess this risk. METHODS: VASc stroke risk score (≥ 2). Required follow-up was at least 3 months. AC was either performed with heparins, phenprocoumon or non-Vitamin K antagonist oral anticoagulants. Applying the propensity score approach, patient cohorts (matched according to primary tumor, age, sex) were generated (GBM [or MET] with AF ± AC, GBM [or MET] without AF/AC, no GBM [or MET] but AF on AC). ICH was defined as clinical deterioration caused by new blood on imaging. A log rank test was performed to compare the risk for ICH between the three groups. RESULTS: In total, 104 patients were identified of which 49 with GBM (37% on AC) and 37 with MET (46% on AC) were successfully matched. Median follow up was 8.6 and 7.2 months, respectively. ICH occurred in 10.2% of GBM + AF and 12.2% GBM-AF, whereas 8% of patients with AF on AC suffered ICH (p = 0.076). 13.5% of patients with MET + AF had ICHs, in the controls it was 16% for MET-AF and 8% for AF on AC (p = 0.11). CONCLUSION: AC did not seem to influence the incidence of ICH in patients with glioblastoma or brain metastases within follow up of just under 9 months.
No takes yet. Share an insight, caveat, or question.
Burth et al. (2021) conducted a cohort in Glioblastoma or brain metastases with atrial fibrillation (n=258). Prophylactic anticoagulation vs. No anticoagulation (tumor controls) or stroke patients on anticoagulation was evaluated on Symptomatic intracranial hemorrhage (sICH) (p=0.076). Prophylactic anticoagulation did not increase the incidence of symptomatic intracranial hemorrhage in patients with glioblastoma or brain metastases compared to controls.
Synapse has enriched 10 related papers. Consider them for comparative context: